ROSE-Longitudinal Assessment With Neuroimaging
The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baselin
| Condition(s) | Intracerebral Hemorrhage |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baseline to determine predictors of recovery, progressive cognitive or functional impairment. The investigators propose to leverage the recruitment, DNA, RNA-seq and baseline advanced neuroimaging cohort of ROSE to obtain long-term neuroimaging and identical assessments longitudinally to address critical questions regarding the progressive decline of patients 12 to 24 months post intracerebral hemorrhage (ICH) with long term cognitive follow-up to 36 months on average. This proposal |
| Who can participate | Inclusion Criteria: * Age 18 years or greater, fulfillment of the criteria for Deep, Subcortical or Lobar Intracerebral Hemorrhage * No evidence of trauma, vascular malformation or aneurysm, or brain tumor as a cause of ICH. * Ability of the patient or legal representative to provide informed consent Exclusion Criteria: * Brainstem or Cerebellar ICH * Patients Severely Affected by the ICH, Early Mortality, Hospice, or Withdraw of Care NOT eligible for ROS |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | State University of New York at Buffalo |
| Locations | Chicago, Illinois, United States; Louisville, Kentucky, United States; Baltimore, Maryland, United States; New York, New York, United States; Durham, North Carolina, United States; Cincinnati, Ohio, United States (+1 more sites) |
| Start date | 2020-09-30 |
| NCT ID | NCT05089331 |
| Official listing | https://clinicaltrials.gov/study/NCT05089331 |